Revelation Biosciences (REVB) announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,355,000 shares of common stock, issued by the Company on May 29, at the existing exercise price of $2.20 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1. The closing of the offering is expected to occur on or about September 11, 2025, subject to satisfaction of customary closing conditions. Roth Capital Partners is acting as the Company’s financial advisor for this transaction.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REVB:
- Revelation Biosciences announces webcast to review Phase 1b PRIME data
- Revelation Biosciences announces topline results from PRIME study
- Revelation Biosciences Announces Positive Phase 1b Study Results
- Morning Movers: Under Armour sinks following second quarter earnings
- Revelation Biosciences reports Q2 EPS ($7.01) vs. ($246.27) last year